Enhanced autologous bone marrow stem cell therapy improves clinical cardiac events in patients with heart failure and reduced ejection fraction resulting from ischemic heart disease and dilated cardiomyopathy.
Globally, percutaneous intra-myocardial delivery of stem cells resulted in a significant 37% reduction in all-cause death, rehospitalization and sudden worsening for heart failure.
This study randomized patients to ixmyelocel-T vs. placebo. Ixmyelocel-T is a derivative of autologous bone marrow that selectively expands mesenchymal stem cells, monocytes, and macrophages.
Autologous bone marrow cells were expanded in vitro for two weeks to selectively increase CD90+ mesenchymal cellsand CD45+ and CD14+ macrophages.
Its success was largely due to a reduction in mortality and rehospitalization rates.
There were no benefits in terms of secondary end point such as ejection fraction, left ventricle volume and 6 minute walk test.
